Avinger slashes jobs, Q3 sales down 61%

Avinger (Nasdaq:AVGR) – maker of the Lumivascular image-guided, catheter-based system to treat peripheral artery disease (PAD) – continued to experience declining sales as it retrenched during the third quarter, according to its newest earnings report. The Redwood, Calif.–based company has been cutting jobs and other costs – and focusing on existing accounts and winning FDA clearance

Avinger inks $15m share purchase deal

Avinger (NSDQ:AVGR) said today it inked a $15 million stock purchase agreement with Lincoln Park Capital Fund. Through the deal, the Redwood City, Calif.–based company said it will have the right and sole discretion to sell $15 million worth of shares over a 30-month period to Lincoln Park Capital, with proceeds slated to support working capital

Avinger shares slide on Q2 miss

Shares in Avinger (NSDQ:AVGR) fell today after the medical device developer missed expectations on Wall Street with its second quarter earnings results. The Redwood City, Calif.-based company posted losses of $12.8 million, or 54¢ per share, on sales of $2.5 million for the 3 months ended June 30, seeing losses shrink 5.2% while sales shrunk 47.5% compared

Clever catheter lets surgeons see inside arteries to trim plaque

The Pantheris catheter developed by Avinger takes the physician out of the radiation field. A clever catheter design lets cardiologists see inside arteries and precisely remove plaque from diseased tissue. The Pantheris catheter is safer than conventional radiation-guided procedures because it takes the surgeon out of the radiation field, and along with on-board optics, it

Avinger shares dive on Q1 miss

Shares in Avinger have fallen over 15% today after the medical device maker missed expectations on Wall Street with its 1st quarter earnings results. The Redwood City, Calif.-based company posted losses of $15.3 million, or 64¢ per share, on sales of $3.5 million for the 3 months ended March 31, seeing losses shrink 5.1% while

Avinger tumbles on Q4 revenue miss

Shares in Avinger (NSDQ:AVGR) dropped today after the medical device maker missed expectations on Wall Street with its 4th quarter results. The Redwood City, Calif.-based company posted losses of -$13.5 million, or -58¢ per share, on sales of $4.7 million for the 3 months ended Dec. 31, for bottom-line loss of -0.3% on sales growth of 64% compared

Avinger Medical upgrades Lightbox imaging console

Avinger, a developer of innovative treatments for peripheral artery disease (PAD), announced the U.S. launch of an enhanced version of the company’s Lightbox imaging console. The Lightbox provides a dual display of images to physicians using Avinger’s Lumivascular system, the first-ever image-guided atherectomy and chronic total occlusion recanalization devices for the treatment of PAD, providing

Avinger inks deal with HealthTrust GPO

Avinger (NSDQ:AVGR) said today it signed an agreement with group purchasing organization HealthTrust for Avinger’s portfolio of peripheral artery disease products. Through the deal, HealthTrust members will be able to purchase Avinger’s Pantheris optical coherence tomography image-guided atherectomy system and other products designed to treat peripheral artery disorder. The Pantheris device is designed to use optical coherence